Ligand Pharmaceuticals (NASDAQ:LGND) Issues FY 2025 Earnings Guidance

Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 6.000-6.250 for the period, compared to the consensus earnings per share estimate of 6.110. The company issued revenue guidance of $180.0 million-$200.0 million, compared to the consensus revenue estimate of $191.3 million.

Ligand Pharmaceuticals Price Performance

Shares of NASDAQ LGND traded down $1.21 during midday trading on Tuesday, reaching $105.17. 90,245 shares of the company traded hands, compared to its average volume of 117,289. Ligand Pharmaceuticals has a 52 week low of $77.43 and a 52 week high of $129.90. The stock has a 50-day moving average price of $106.41 and a 200 day moving average price of $112.42. The company has a market cap of $2.03 billion, a price-to-earnings ratio of 41.90 and a beta of 0.87.

Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biotechnology company reported $1.33 earnings per share for the quarter, beating analysts' consensus estimates of $1.23 by $0.10. The business had revenue of $45.33 million for the quarter, compared to analysts' expectations of $37.84 million. Ligand Pharmaceuticals had a net margin of 29.68% and a return on equity of 4.95%. During the same period in the previous year, the business earned $3.84 earnings per share. As a group, analysts expect that Ligand Pharmaceuticals will post 1.73 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on LGND. Stifel Nicolaus began coverage on Ligand Pharmaceuticals in a report on Thursday, April 10th. They set a "buy" rating and a $143.00 target price on the stock. Oppenheimer lifted their price target on Ligand Pharmaceuticals from $142.00 to $145.00 and gave the stock an "outperform" rating in a research note on Friday. Finally, StockNews.com cut Ligand Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $146.14.

Insider Buying and Selling at Ligand Pharmaceuticals

In other news, CFO Octavio Espinoza sold 5,000 shares of Ligand Pharmaceuticals stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $115.03, for a total transaction of $575,150.00. Following the completion of the sale, the chief financial officer now directly owns 18,879 shares in the company, valued at $2,171,651.37. The trade was a 20.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 5.90% of the company's stock.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.